Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The new queen of country music has no scandals and no gimmicks — and just broke a record set by Taylor Swift - 2WATCH: IDF strikes, dismantles missile launchers in southern Lebanon
- 3Discovering a true sense of harmony: Contemplation and Care Practices
- 4the Kinds of Thailand: Decision in favor of Your Number one Thai Dish!
- 5What to know about the hepatitis B shot — and why Trump officials are targeting it
- Flash flooding causes highways to close to and from Eilat
- 4 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- In a first, scientists observe a comet reversing its spin
- Spain and Catholic Church agree to compensate sex abuse victims
- 10 Natural products to Remember for Your Eating routine for a Better You
- Trump administration launches new immigration crackdowns in New Orleans and Minneapolis. Here are all the cities it has targeted so far.
- Instructions to Warmly greet Discretion and Thoughtfulness
- Top notch DSLR Cameras for Photography Devotees
